Crescent Biopharma
As of the edition of 20 October 2026, Crescent Biopharma runs 4 drugs; it is on route A at 4 targets and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 2 company names in this family.
- GlycoMimetics Incorporated: renamed
Drugs by status
| Status | Count |
|---|---|
| Active | 1 |
| Stopped | 3 |
| Total | 4 |
Where it needs a new molecule
Route A at 4 targets, route B at 0 targets.
All 4 rows on route A or B
In the product4 company-target rows on route A or B; 1 is not shown here, and no score is.
See all 4 targets where Crescent Biopharma needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Blood and lymph: 6 trials led
- Cancer: 5 trials led
- Inherited and neonatal: 3 trials led